GRF(1-29) is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-15. Numbers and descriptions here follow the published literature rather than marketing material.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
== Hydrogen-6 == 6H (atomic mass 6.04496(27) Da) has one proton and five neutrons. It has a half-life of 294(67) ys (2.94(67)×10−22 s). In 2025, 6H was produced using an 855 MeV electron beam impinging upon on a 7Li target.
=== Aftermath === Rumours circulated of a brain haemorrhage, followed by competing reports of a mugging or even that Thomas had drunk himself to death. Later, speculation arose about drugs and diabetes. At the post-mortem, the pathologist found three causes of death—pneumonia, brain swelling and a fatty liver. His liver showed no sign of cirrhosis. Many sources have criticised Feltenstein's role and actions, especially his incorrect diagnosis of delirium tremens and the high dose of morphine he administered. Dr C. G. de Gutierrez-Mahoney, the neurosurgeon who treated Thomas while at St. Vincents, concluded that Feltenstein's failure to see that Thomas was gravely ill and have him admitted to hospital sooner "was even more culpable than his use of morphine". The publication of John Brinnin's 1955 biography Dylan Thomas in America cemented Thomas's reputation as a "roistering, drunken and doomed poet"; Brinnin focuses on Thomas's last few years and paints a picture of him as a drunk and a philanderer. Later biographies have criticised Brinnin's view, especially his coverage of Thomas's death. David Thomas in Fatal Neglect: Who Killed Dylan Thomas? writes that Brinnin, along with Reitell and Feltenstein, were culpable. Ferris in his 1989 biography references Thomas's heavy drinking, but is more critical of those around him in his final days and does not draw the conclusion that he drank himself to death.
A sphinx ( SFINKS; Ancient Greek: σφίγξ, pronounced [spʰíŋks]; pl. sphinxes or sphinges ) is a mythical creature with the head of a human, the body of a lion, and the wings of an eagle. In Greek tradition, the sphinx is a treacherous and merciless being with the head of a woman, the haunches of a lion, and the wings of a bird. According to Greek myth, she challenges those who encounter her to answer a riddle, and kills and eats them when they fail to solve the riddle. This deadly version of a sphinx appears in the myth and drama of Oedipus. In Egyptian mythology, in contrast, the sphinx is typically depicted as a man (an androsphinx (Ancient Greek: ἀνδρόσφιγξ)), and is seen as a benevolent representation of strength and ferocity, usually of a pharaoh. Unlike Greek or Levantine/Mesopotamian ones, Egyptian sphinxes were not winged. Both the Greek and Egyptian sphinxes were thought of as guardians, and statues of them often flank the entrances to temples. During the Renaissance, the sphinx enjoyed a major revival in European decorative art. During this period, images of the sphinx were initially similar to the ancient Egyptian version, but when later exported to other cultures, the sphinx was often conceived of quite differently, partly due to varied translations of descriptions of the originals, and partly through the evolution of the concept as it was integrated into other cultural traditions. However, depictions of the sphinx are generally associated with grand architectural structures, such as royal tombs or religious temples.
The arachnoid layer was first described by Dutch physician Gerardus Blasius in 1664. In 1695, Humphrey Ridley first described the subarachnoid cisterns. He also contributed to the understanding of the blood-brain barrier, and accurately described the fifth cranial nerve ganglion with its branches. In 1699, Frederick Ruysch confirmed that the arachnoid mater formed a complete layer that surrounded the brain. Its current name is based on his description of its spiderlike morphology. Arachnoid granulations were first described by Italian physician Antonio Pacchioni who published his Dissertatio Epistolaris de Glandulis Conglobatis Durae Meningis Humanae in 1705. In seven articles from 1899 to 1902, Italian anatomist Giuseppe Sterzi described comparative studies on the meninges from the lancelet to the human. He showed that the spinal meninges were very simple in adult lower vertebrates and in the early development of more advanced vertebrates.
=== Nausea and vomiting === Intravenous dexamethasone is effective for the prevention of nausea and vomiting in people who had surgery and whose post-operative pain was treated with long-acting spinal or epidural spinal opioids. The combination of dexamethasone and a 5-HT3 receptor antagonist such as ondansetron is more effective than a 5-HT3 receptor antagonist alone in preventing postoperative nausea and vomiting.
Sources: en.wikipedia.org
=== Broadcasters === Robert Siegel (1968), host of All Things Considered on National Public Radio Jim Gardner (1970), anchor for WPVI-TV news in Philadelphia Christopher Kimball (1973), celebrity chef, editor-in-chief of Cook's Illustrated and host of America's Test Kitchen George Whipple III (1977), lawyer and society correspondent for NY1 Pimm Fox (1982), Bloomberg Radio and Bloomberg Television anchorman Fred Katayama (1982), anchor on Reuters Television James Rubin (1982), Sky News anchorman; former assistant secretary of state for public affairs in the Clinton Administration; spokesman for the presidential campaigns of Wesley Clark and John Kerry; husband of Christiane Amanpour George Stephanopoulos (1982), ABC News personality; senior advisor to U.S.
MedPlus was founded in 2006 by Madhukar Gangadi. The company's first store was launched in Hyderabad. Initially operating under the Aushadhi brand name, it was rebranded as MedPlus after the opening of the first 48 stores. The company opened pharmacies in the western states of Gujarat and Rajasthan in 2007 but had to shut down and exit operations due to recurring losses. It relaunched stores in Ahmedabad, Gujarat in 2014. In 2008, it opened diagnostics centers in five cities under its subsidiary MedPlus Pathlabs. In 2015, it started its e-pharmacy division. In December 2021, MedPlus Health Services launched its initial public offering (IPO) and got listed on the Indian stock exchanges.
=== Pain === The weak opioid codeine, in low doses and combined with one or more other drugs, is available in prescription medicines and, in some jurisdictions, without a prescription to treat mild pain. Other opioids are usually reserved for the relief of moderate to severe pain.
Deupsilocin (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; former developmental code names HLP003 and CYB0003), also known as deuterated psilocin or as psilocin-d10, is a psychedelic drug of the tryptamine family related to psilocin which is under development for the treatment of major depressive disorder, alcoholism, and other psychiatric disorders. It is taken orally. The drug is a deuterated isotopologue of psilocin with altered pharmacokinetics.
Hence, blood with high carbon dioxide levels is also lower in pH (more acidic). Hemoglobin can bind protons and carbon dioxide, which causes a conformational change in the protein and facilitates the release of oxygen. Protons bind at various places on the protein, while carbon dioxide binds at the α-amino group. Carbon dioxide binds to hemoglobin and forms carbaminohemoglobin. This decrease in hemoglobin's affinity for oxygen by the binding of carbon dioxide and acid is known as the Bohr effect. The Bohr effect favors the T state rather than the R state. (shifts the O2-saturation curve to the right). Conversely, when the carbon dioxide levels in the blood decrease (i.e., in the lung capillaries), carbon dioxide and protons are released from hemoglobin, increasing the oxygen affinity of the protein. A reduction in the total binding capacity of hemoglobin to oxygen (i.e. shifting the curve down, not just to the right) due to reduced pH is called the root effect. This is seen in bony fish. It is necessary for hemoglobin to release the oxygen that it binds; if not, there is no point in binding it. The sigmoidal curve of hemoglobin makes it efficient in binding (taking up O2 in lungs), and efficient in unloading (unloading O2 in tissues). In people acclimated to high altitudes, the concentration of 2,3-Bisphosphoglycerate (2,3-BPG) in the blood is increased, which allows these individuals to deliver a larger amount of oxygen to tissues under conditions of lower oxygen tension.
Sources: en.wikipedia.org
== Formation == Chondrocytes develop in the embryo from mesenchymal progenitor cells through a process known as chondrogenesis. A chondrocyte can then undergo mitosis to form an isogenous group within its lacuna.
=== Transportation companies === Canadian Airlines (1987–2001) (IATA airline code CP) Canadian Pacific Railway, reporting mark CP Central Pacific Railroad, a network of lines between California and Utah, US Chemins de Fer de Provence, a French public railway company Comboios de Portugal, a Portuguese state-owned train company CP Air or Canadian Pacific Air Lines (1942–1987), a Canadian airline CP Ships, a Canadian shipping company, part of TUI Group Cathay Pacific, a Hong Kong–based major airline
The practice of drying starchy root vegetables for preservation and portability is widely attested around the world, and likely dates back to before the advent of agriculture. Potatoes in particular have been freeze dried since at least the time of the Inca Empire, in the form of chuño; another example is in Japanese Ainu cuisine, where potatoes are collected frozen from the ground in spring, then dried. U.S. Patent 1025373, developed by Ernest William Cooke, titled "Dehydrate Potatoes and Process of Preparing the Same", and describing a product that was to be reconstituted in hot water, was applied for in 1905 and granted in 1912. Flake-form instant mashed potatoes date back at least to 1954, when two United States Department of Agriculture researchers were issued a patent for "Drum drying of cooked mashed potatoes" (U.S. Patent 2,759,832), which describes the end product specifically being "as a thin sheet or flake". In 1962, Canadian scientist Edward A. Asselbergs was issued U.S. Patent 3,260,607, entitled "Preparation of dehydrated cooked mashed potato", for a particular industrial method of producing the product.
== Mechanical bonding and chemical reactivity == The introduction of a mechanical bond alters the chemistry of the sub components of rotaxanes and catenanes. Steric hindrance of reactive functionalities is increased and the strength of non-covalent interactions between the components are altered.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.